IVERIC bio, Inc. Profile Avatar - Palmy Investing

IVERIC bio, Inc.

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]

Cash Flow Statements

12 Sheets · Starting from 2022
In Million USD. Margins, Growth Rates In %
Metric 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Operating Activities
Operating Cash Flow (OCF)
-19.00 -13.00 -48.00 111.00 -78.00 -108.00 -121.00 -41.00 -48.00 -66.00 -98.00 -163.00
Operating Cash (Net)
-19.00 -13.00 -48.00 111.00 -78.00 -108.00 -121.00 -41.00 -48.00 -66.00 -98.00 -163.00
Accounts Receivable
- - - - - - - - -3.00 - - 3.00 - - - - - - - - - -
Accounts Payable
- - - - 2.00 4.00 3.00 - - -4.00 -1.00 - - 7.00 - - 9.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
3.00 - - - - -427.00 247.00 13.00 154.00 - - - - -143.00 21.00 -50.00
Capital Expenditure
- - - - - - -1.00 -2.00 - - - - - - - - - - - - - -
Purchases of Investments
- - - - - - -597.00 -411.00 -72.00 -12.00 - - - - -143.00 -142.00 -231.00
Sale/Maturity of Investment
3.00 - - - - 171.00 661.00 86.00 166.00 - - - - - - 164.00 180.00
Property, Plant, Equipment (P&PE)
- - - - - - -1.00 -2.00 - - - - - - - - - - - - - -
Acquisitions (Net)
- - - - - - - - - - - - - - - - - - - - - - - -
Other Investing Activities
- - - - - - - - - - - - - - - - - - - - - - - -
Financing Activities
Used Cash (Net)
-14.00 -11.00 -255.00 -145.00 -12.00 -6.00 - - -6.00 -42.00 -150.00 -272.00 -428.00
Debt Repayment
- - - - -11.00 - - - - - - - - - - - - - - - - - -
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - 169 - - - - - - - - - - - - - - - - - -
Other Financing Activities
14.00 11.00 91.00 90.00 12.00 6.00 - - - - - - - - 2.00 104.00
Cash Balances
Begin of Period
7.00 6.00 4.00 210.00 39.00 221.00 133.00 166.00 131.00 125.00 66.00 261.00
End of Period
6.00 4.00 210.00 39.00 221.00 133.00 166.00 131.00 125.00 66.00 261.00 476.00
Change
- - -2.00 206.00 -170.00 182.00 -87.00 33.00 -35.00 -5.00 -59.00 195.00 214.00
Non-Cash Balances
Depreciation and Amortization
- - - - - - - - - - - - 2.00 - - - - - - - - - -
Stock Based Compensation
- - - - - - - - - - - - - - - - 9.00 8.00 11.00 26.00
Other
- - - - 2.00 -2.00 1.00 - - - - -119.00 - - - - - - - -
Highlighted metrics
Free Cash Flow (FCF)
-19.00 -13.00 -48.00 109.00 -81.00 -109.00 -121.00 -41.00 -48.00 -66.00 -98.00 -164.00
Cash Conversion Cycle (CCC)
- - - - - - - - - - - - - - - - - - - - - - - -
Invested Capital
- - - - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of ISEE's Analysis
CIK: 1410939 CUSIP: 46583P102 ISIN: US46583P1021 LEI: - UEI: -
Secondary Listings
ISEE has no secondary listings inside our databases.